|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DELE1 |
Gene summary for DELE1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DELE1 | Gene ID | 9812 |
| Gene name | DAP3 binding cell death enhancer 1 | |
| Gene Alias | DELE | |
| Cytomap | 5q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q14154 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9812 | DELE1 | S014 | Human | Liver | HCC | 2.05e-19 | 5.06e-01 | 0.2254 |
| 9812 | DELE1 | S015 | Human | Liver | HCC | 5.29e-18 | 7.16e-01 | 0.2375 |
| 9812 | DELE1 | S016 | Human | Liver | HCC | 3.82e-21 | 5.33e-01 | 0.2243 |
| 9812 | DELE1 | S027 | Human | Liver | HCC | 1.01e-07 | 4.63e-01 | 0.2446 |
| 9812 | DELE1 | S028 | Human | Liver | HCC | 5.14e-14 | 4.61e-01 | 0.2503 |
| 9812 | DELE1 | S029 | Human | Liver | HCC | 4.51e-24 | 7.40e-01 | 0.2581 |
| 9812 | DELE1 | male-WTA | Human | Thyroid | PTC | 2.18e-22 | 2.78e-01 | 0.1037 |
| 9812 | DELE1 | PTC01 | Human | Thyroid | PTC | 5.85e-06 | 1.35e-01 | 0.1899 |
| 9812 | DELE1 | PTC03 | Human | Thyroid | PTC | 5.01e-06 | 2.71e-01 | 0.1784 |
| 9812 | DELE1 | PTC04 | Human | Thyroid | PTC | 1.45e-16 | 2.98e-01 | 0.1927 |
| 9812 | DELE1 | PTC05 | Human | Thyroid | PTC | 1.25e-14 | 4.51e-01 | 0.2065 |
| 9812 | DELE1 | PTC06 | Human | Thyroid | PTC | 9.59e-27 | 5.11e-01 | 0.2057 |
| 9812 | DELE1 | PTC07 | Human | Thyroid | PTC | 1.20e-21 | 3.54e-01 | 0.2044 |
| 9812 | DELE1 | ATC09 | Human | Thyroid | ATC | 6.18e-03 | 1.61e-01 | 0.2871 |
| 9812 | DELE1 | ATC12 | Human | Thyroid | ATC | 5.11e-12 | 2.63e-01 | 0.34 |
| 9812 | DELE1 | ATC13 | Human | Thyroid | ATC | 1.19e-10 | 2.18e-01 | 0.34 |
| 9812 | DELE1 | ATC1 | Human | Thyroid | ATC | 1.55e-03 | 1.88e-01 | 0.2878 |
| 9812 | DELE1 | ATC2 | Human | Thyroid | ATC | 9.94e-09 | 9.04e-01 | 0.34 |
| 9812 | DELE1 | ATC3 | Human | Thyroid | ATC | 6.30e-07 | 4.47e-01 | 0.338 |
| 9812 | DELE1 | ATC4 | Human | Thyroid | ATC | 1.23e-16 | 3.60e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009719122 | Liver | HCC | extrinsic apoptotic signaling pathway | 143/7958 | 219/18723 | 6.99e-12 | 2.97e-10 | 143 |
| GO:004328112 | Liver | HCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 125/7958 | 209/18723 | 3.12e-07 | 5.42e-06 | 125 |
| GO:200011612 | Liver | HCC | regulation of cysteine-type endopeptidase activity | 137/7958 | 235/18723 | 6.91e-07 | 1.08e-05 | 137 |
| GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
| GO:005254822 | Liver | HCC | regulation of endopeptidase activity | 230/7958 | 432/18723 | 3.58e-06 | 4.68e-05 | 230 |
| GO:000862511 | Liver | HCC | extrinsic apoptotic signaling pathway via death domain receptors | 55/7958 | 82/18723 | 5.97e-06 | 7.35e-05 | 55 |
| GO:0097191113 | Thyroid | PTC | extrinsic apoptotic signaling pathway | 117/5968 | 219/18723 | 2.73e-11 | 1.03e-09 | 117 |
| GO:000862523 | Thyroid | PTC | extrinsic apoptotic signaling pathway via death domain receptors | 47/5968 | 82/18723 | 1.70e-06 | 2.38e-05 | 47 |
| GO:0043281113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 99/5968 | 209/18723 | 1.93e-06 | 2.64e-05 | 99 |
| GO:2000116113 | Thyroid | PTC | regulation of cysteine-type endopeptidase activity | 108/5968 | 235/18723 | 3.99e-06 | 4.99e-05 | 108 |
| GO:0052547113 | Thyroid | PTC | regulation of peptidase activity | 191/5968 | 461/18723 | 7.82e-06 | 9.02e-05 | 191 |
| GO:0052548113 | Thyroid | PTC | regulation of endopeptidase activity | 174/5968 | 432/18723 | 1.20e-04 | 9.55e-04 | 174 |
| GO:0097191210 | Thyroid | ATC | extrinsic apoptotic signaling pathway | 125/6293 | 219/18723 | 7.19e-13 | 3.16e-11 | 125 |
| GO:0008625111 | Thyroid | ATC | extrinsic apoptotic signaling pathway via death domain receptors | 50/6293 | 82/18723 | 3.47e-07 | 5.13e-06 | 50 |
| GO:004328133 | Thyroid | ATC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 102/6293 | 209/18723 | 3.61e-06 | 4.03e-05 | 102 |
| GO:005254734 | Thyroid | ATC | regulation of peptidase activity | 200/6293 | 461/18723 | 6.25e-06 | 6.52e-05 | 200 |
| GO:200011633 | Thyroid | ATC | regulation of cysteine-type endopeptidase activity | 111/6293 | 235/18723 | 9.41e-06 | 9.41e-05 | 111 |
| GO:005254834 | Thyroid | ATC | regulation of endopeptidase activity | 181/6293 | 432/18723 | 1.70e-04 | 1.16e-03 | 181 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |